Results : 1 - 3 of 3
-
Predictors as well as surrogate and hard endpoints in cardiovascular disease
By Thomas F. Lüscher 2015-09-01
Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast New therapies in cardiovascular disease are best evaluated with outcome trials comparing event rates between a new therapy and placebo, or between a new therapy and a previously ...
Semantic footprint
-
Predictors as well as surrogate and hard endpoints in cardiovascular disease
By Lüscher, Thomas F. 2015-09-01
Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast New therapies in cardiovascular disease are best evaluated with outcome trials comparing event rates between a new therapy and placebo, or between a new therapy and a previously ...
Semantic footprint
-
Predictors as well as surrogate and hard endpoints in cardiovascular disease
By Lüscher, Thomas F. 2015-09-01
Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast New therapies in cardiovascular disease are best evaluated with outcome trials comparing event rates between a new therapy and placebo, or between a new therapy and a previously ...
Semantic footprint
Applied filters
Concept
- cardiac hypertrophy 3
- cardiogenic shock 3
- cardiovascular disease 3
- clinical research 3
- clinical trials 3
- end-systolic volume 3
- endomyocardial injection 3
- entry pathway 3
- extracorporeal membrane oxygenation 3
- ischaemic heart failure 3
- knockout mice 3
- medical therapy 3
- refractory cardiogenic shock 3
- renal denervation 3
- surrogate endpoint 3